Skip to main content

MoneyWorks4Me

Emmessar Biotech&Nut - Quaterly Results

01 Nov 2026 Evaluate
The revenue for the September 2026 quarter is pegged at Rs. 1.09 millions, about 18.48% up against Rs. 0.92 millions recorded during the year-ago period.Profit saw a slight increase of 23.89%to Rs. 1.40  millions from Rs. 1.13 millions.Operating profit for the quarter ended September 2026 rose to 1.96 millions as compared to 1.65 millions of corresponding quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 1.09 0.92 18.48 1.68 1.85 -9.19 3.71 6.11 -39.28
Other Income 5.16 5.39 -4.27 10.55 10.73 -1.68 20.36 20.09 1.34
PBIDT 1.96 1.65 18.79 3.82 4.22 -9.48 6.83 10.58 -35.44
Interest 0.01 0.01 0.00 0.02 0.02 0.00 0.02 0.01 100.00
PBDT 1.95 1.64 18.90 3.80 4.20 -9.52 6.81 10.57 -35.57
Depreciation 0.23 0.25 -8.00 0.46 0.50 -8.00 1.00 0.98 2.04
PBT 1.72 1.39 23.74 3.34 3.70 -9.73 5.81 9.59 -39.42
TAX 0.32 0.26 23.08 0.64 0.86 -25.58 1.44 6.42 -77.57
Deferred Tax -0.11 -0.10 10.00 -0.20 -0.10 100.00 -0.37 2.02 -118.32
PAT 1.40 1.13 23.89 2.70 2.84 -4.93 4.37 3.17 37.85
Equity 49.96 49.96 0.00 49.96 49.96 0.00 49.96 49.96 0.00
PBIDTM(%) 179.82 179.35 0.26 227.38 228.11 -0.32 184.10 173.16 6.32
Peers
Company Name CMP
Sun Pharma. Inds. 1776.00
Dr. Reddys Labs. 1372.00
Cipla 1400.10
Lupin 2015.00
Zydus Lifesciences 1190.00
View more..